title: Effect of tumor necrosis factor-α inhibitors on ambulatory 24-h blood pressure.
abstract: Tumor necrosis factor alpha (TNF-α) inhibitors are increasingly being used in inflammatory rheumatic diseases (IRD). The risk of cardiovascular disease is elevated in patients with IRD and TNF-α inhibitors reduce this risk. We assessed whether the beneficial effect of TNF-α inhibitors on cardiovascular risk is mediated by blood pressure reduction. We measured blood pressure levels with 24-h ambulatory blood pressure measurements device in patients with IRD before and 3 months after treatment with TNF-α inhibitors. The study population consisted of 15 subjects (6 men; mean age 45.9 ± 14.1 years). Most patients had either rheumatoid arthritis or psoriatic arthritis and adalimumab was the most common TNF-α inhibitor used. Mean 24-h systolic and diastolic blood pressure levels remained the same after treatment (121 ± 12/66 ± 7 before and 123 ± 11/67 ± 10 mm Hg after; p = 0.88 and 0.66, respectively). The study demonstrates that TNF-α inhibitors have no effect on blood pressure levels.
authors.affiliation: a Department of Internal Medicine F and the Rheumatology Unit , The Chaim Sheba Medical Center , Tel-Hashomer , Israel.|b Sackler Faculty of Medicine , Tel-Aviv University , Tel-Aviv , Israel.
authors.forename: Chagai
authors.initials: C
authors.lastname: Grossman
authors.affiliation: b Sackler Faculty of Medicine , Tel-Aviv University , Tel-Aviv , Israel.|c Department of Internal Medicine D and Hypertension Unit , The Chaim Sheba Medical Center , Tel-Hashomer , Israel.
authors.forename: Gil
authors.initials: G
authors.lastname: Bornstein
authors.affiliation: b Sackler Faculty of Medicine , Tel-Aviv University , Tel-Aviv , Israel.|c Department of Internal Medicine D and Hypertension Unit , The Chaim Sheba Medical Center , Tel-Hashomer , Israel.
authors.forename: Avshalom
authors.initials: A
authors.lastname: Leibowitz
authors.affiliation: a Department of Internal Medicine F and the Rheumatology Unit , The Chaim Sheba Medical Center , Tel-Hashomer , Israel.|b Sackler Faculty of Medicine , Tel-Aviv University , Tel-Aviv , Israel.
authors.forename: Ilan
authors.initials: I
authors.lastname: Ben-Zvi
authors.affiliation: b Sackler Faculty of Medicine , Tel-Aviv University , Tel-Aviv , Israel.|c Department of Internal Medicine D and Hypertension Unit , The Chaim Sheba Medical Center , Tel-Hashomer , Israel.
authors.forename: Ehud
authors.initials: E
authors.lastname: Grossman
mesh_terms: D000068879:Adalimumab / Q000008:administration & dosage*; D000328:Adult; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000503:physiopathology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects*; D018660:Blood Pressure Monitoring, Ambulatory; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab
keywords: Ambulatory blood pressure monitoring; TNF-α inhibitors; inflammatory rheumatic diseases